Michel Dahan - 12 May 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Operating Officer
Signature
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
Issuer symbol
AKBA
Transactions as of
12 May 2023
Net transactions value
$0
Form type
4
Filing time
16 May 2023, 16:09:54 UTC
Previous filing
03 Mar 2023
Next filing
25 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +200,000 +74% $0.000000 469,515 12 May 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.